DK174125B1 - Farmaceutisk præparat til parenteral indgivelse indeholdende en somatostatinanalog, mælkesyre og en basisk forbindelse - Google Patents

Farmaceutisk præparat til parenteral indgivelse indeholdende en somatostatinanalog, mælkesyre og en basisk forbindelse Download PDF

Info

Publication number
DK174125B1
DK174125B1 DK198803854A DK385488A DK174125B1 DK 174125 B1 DK174125 B1 DK 174125B1 DK 198803854 A DK198803854 A DK 198803854A DK 385488 A DK385488 A DK 385488A DK 174125 B1 DK174125 B1 DK 174125B1
Authority
DK
Denmark
Prior art keywords
alkyl
hydrogen
phe
lys
amino
Prior art date
Application number
DK198803854A
Other languages
Danish (da)
English (en)
Other versions
DK385488D0 (da
DK385488A (da
Inventor
Thomas Cavanak
Alan Harris
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878716326A external-priority patent/GB8716326D0/en
Priority claimed from GB878716324A external-priority patent/GB8716324D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DK385488D0 publication Critical patent/DK385488D0/da
Publication of DK385488A publication Critical patent/DK385488A/da
Priority to DK200100558A priority Critical patent/DK174476B1/da
Application granted granted Critical
Publication of DK174125B1 publication Critical patent/DK174125B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
DK198803854A 1987-07-10 1988-07-08 Farmaceutisk præparat til parenteral indgivelse indeholdende en somatostatinanalog, mælkesyre og en basisk forbindelse DK174125B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200100558A DK174476B1 (da) 1987-07-10 2001-04-04 Anvendelse af octreotid til fremstilling af et lægemiddel til behandling af brystkræft

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8716324 1987-07-10
GB8716326 1987-07-10
GB878716326A GB8716326D0 (en) 1987-07-10 1987-07-10 Organic compounds
GB878716324A GB8716324D0 (en) 1987-07-10 1987-07-10 Organic compounds

Publications (3)

Publication Number Publication Date
DK385488D0 DK385488D0 (da) 1988-07-08
DK385488A DK385488A (da) 1989-01-11
DK174125B1 true DK174125B1 (da) 2002-07-01

Family

ID=26292476

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198803854A DK174125B1 (da) 1987-07-10 1988-07-08 Farmaceutisk præparat til parenteral indgivelse indeholdende en somatostatinanalog, mælkesyre og en basisk forbindelse
DK200100558A DK174476B1 (da) 1987-07-10 2001-04-04 Anvendelse af octreotid til fremstilling af et lægemiddel til behandling af brystkræft

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200100558A DK174476B1 (da) 1987-07-10 2001-04-04 Anvendelse af octreotid til fremstilling af et lægemiddel til behandling af brystkræft

Country Status (27)

Country Link
US (2) US5753618A (sv)
JP (1) JP2578477B2 (sv)
AU (1) AU618270B2 (sv)
BE (1) BE1001079A4 (sv)
CA (1) CA1328402C (sv)
CH (1) CH677449A5 (sv)
CS (1) CS411591A3 (sv)
CY (2) CY1632A (sv)
DE (2) DE3822557C2 (sv)
DK (2) DK174125B1 (sv)
ES (1) ES2010561A6 (sv)
FI (1) FI93308C (sv)
FR (1) FR2617714B1 (sv)
GB (1) GB2208200B (sv)
GR (1) GR1000172B (sv)
HK (1) HK16492A (sv)
HU (1) HU203480B (sv)
IE (1) IE61908B1 (sv)
IL (1) IL87044A0 (sv)
LU (1) LU87268A1 (sv)
MY (2) MY109309A (sv)
NL (1) NL194823C (sv)
NO (1) NO179359C (sv)
NZ (1) NZ225340A (sv)
PT (1) PT87957B (sv)
SE (2) SE503191C2 (sv)
SG (1) SG3692G (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813339D0 (en) * 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5626945A (en) * 1993-09-28 1997-05-06 International Paper Company Repulpable, water repellant paperboard
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
IL158922A0 (en) * 2001-06-08 2004-05-12 Sod Conseils Rech Applic Somatostatin-dopamine chimeric analogs
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
US20030207811A1 (en) * 2002-05-03 2003-11-06 Schrier Bruce K. Method of treating retinopathy of prematurity using somatostatin analogs
EP1787658B1 (en) 2005-11-10 2012-03-14 CHEMI S.p.A. Sustained release formulations of somatostatin analogue inhibitors of growth hormone
CA2647986C (en) * 2006-03-31 2014-07-08 Erasmus University Medical Center Rotterdam Compositions for tumor growth control
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
WO2012074559A2 (en) * 2010-12-02 2012-06-07 New York University Treatment of non-proliferative cystic disease
EP2714064B1 (en) * 2011-06-02 2019-05-15 The Regents of The University of California Blockade of inflammatory proteases with theta-defensins
WO2014070965A2 (en) 2012-11-01 2014-05-08 Ipsen Pharma S.A.S Somatostatin analogs and dimers thereof
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621770A5 (en) * 1976-02-23 1981-02-27 Sandoz Ag Process for the preparation of novel peptide compounds
IT1105131B (it) * 1977-06-08 1985-10-28 Merck & Co Inc Peptidi analoghi della somatostatina dotati di piu' lunga e maggiore attivita' biologica e relativo procedimento di protezione
LU78191A1 (de) * 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
US4374060A (en) * 1981-07-15 1983-02-15 Merck & Co., Inc. Process for the preparation of cyclic hexapeptide
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
US4522813A (en) * 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
NL8503426A (nl) * 1984-12-24 1986-07-16 Sandoz Ag 8alfa-acylamino-ergolinen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
GR862206B (en) * 1985-09-12 1986-12-31 Univ Tulane Therapeutic somatostatin analogs
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
HU906341D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
AU639371B2 (en) * 1987-07-10 1993-07-22 Novartis Ag Method of treating breast cancer
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
AU2284588A (en) * 1988-09-26 1990-03-29 Sandoz Ltd. Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体

Also Published As

Publication number Publication date
FI883261A (sv) 1989-01-11
DK200100558A (da) 2001-04-04
SE9301290A0 (sv) 1993-04-20
AU1889388A (en) 1989-01-12
IL87044A0 (en) 1988-12-30
SE9301290D0 (sv) 1993-04-20
NL194823C (nl) 2003-04-03
NO883054D0 (no) 1988-07-08
NL194823B (nl) 2002-12-02
FI883261A0 (sv) 1988-07-08
ES2010561A6 (es) 1989-11-16
PT87957A (pt) 1989-06-30
IE882091L (en) 1989-01-10
GB2208200B (en) 1991-11-27
DE3845000C2 (de) 1998-11-19
DK174476B1 (da) 2003-04-14
CY1631A (en) 1992-07-10
MY103746A (en) 1993-09-30
HU203480B (en) 1991-08-28
US6066616A (en) 2000-05-23
AU618270B2 (en) 1991-12-19
CS411591A3 (en) 1992-06-17
NO179359B (no) 1996-06-17
HUT47865A (en) 1989-04-28
FI93308C (sv) 1995-03-27
FR2617714A1 (fr) 1989-01-13
JPS6431728A (en) 1989-02-02
JP2764041B2 (ja) 1998-06-11
CY1632A (en) 1992-07-10
GR1000172B (el) 1991-11-15
MY109309A (en) 1997-01-31
IE61908B1 (en) 1994-11-30
LU87268A1 (fr) 1989-03-08
GR880100458A (en) 1989-04-12
DK385488D0 (da) 1988-07-08
NZ225340A (en) 1991-05-28
GB2208200A (en) 1989-03-15
FI93308B (sv) 1994-12-15
DE3822557A1 (de) 1989-01-19
SE503191C2 (sv) 1996-04-15
NO883054L (no) 1989-01-11
US5753618A (en) 1998-05-19
NL8801734A (nl) 1989-02-01
PT87957B (pt) 1995-03-01
CH677449A5 (sv) 1991-05-31
JP2578477B2 (ja) 1997-02-05
JPH0748272A (ja) 1995-02-21
SG3692G (en) 1992-03-20
SE8802569D0 (sv) 1988-07-08
NO179359C (no) 1996-09-25
DK385488A (da) 1989-01-11
CA1328402C (en) 1994-04-12
SE8802569L (sv) 1989-01-11
HK16492A (en) 1992-03-06
BE1001079A4 (fr) 1989-07-04
FR2617714B1 (fr) 1991-09-20
DE3822557C2 (de) 1998-07-02
GB8816024D0 (en) 1988-08-10

Similar Documents

Publication Publication Date Title
DK174125B1 (da) Farmaceutisk præparat til parenteral indgivelse indeholdende en somatostatinanalog, mælkesyre og en basisk forbindelse
Gola et al. Resistance to somatostatin analogs in acromegaly: an evolving concept?
Chiodini et al. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients
ES2681023T3 (es) Terapia de combinación para tratar el déficit de andrógenos
JP5582477B2 (ja) 非閉経女性における卵胞貯蔵を調節するのに意図した医薬を製造するのにソマトスタチン又はその同族体の１つの使用
LAMBERTS et al. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201–995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a
EP0351354A2 (en) Somatostatin derivatives for the treatment of arthritis
WANG et al. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly
KR100195894B1 (ko) 소마토스타틴 동족체를 함유하는 약학 조성물
JP2764041B6 (ja) ソマトスタチン類に関する改良
Smythe et al. Rapid induction of prolactin secretion by 3-iodo-L-tyrosine
GB2239178A (en) Somatostatin analogues for the treatment of breast cancer
JPH02149528A (ja) 肺保護剤
Foresta et al. Naloxone reduces the fenfluramine‐induced prolactin release in man
Smythe et al. Blockade of serotonin induced GH secretion in rats by melatonin and cyproheptadine
KNIGGE et al. Histaminergic regulation of prolactin secretion: dose-response relationship and possible involvement of the dopaminergic system
Bloom Acromegaly
WO2002009739A1 (en) Treatment of ocular disorders with somatostatin analogues
Kaliszuk et al. The influence of bromocriptine on sexual activity in ethanol-exposed male rats
Ahmad et al. Hypoprolactinemia following intradermal administration of ouabain in Uromastix hardwickii

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired